-
1
-
-
0026761441
-
Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens
-
Rosen MA, Goldstone L, Lapin S et al. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 1992; 148: 331.
-
(1992)
J Urol
, vol.148
, pp. 331
-
-
Rosen, M.A.1
Goldstone, L.2
Lapin, S.3
-
2
-
-
0020660916
-
Understaging and undergrading of prostate cancer; argument for postoperative radiation as adjuvant therapy
-
Lange PH, Narayan P. Understaging and undergrading of prostate cancer; argument for postoperative radiation as adjuvant therapy. Urology 1983; 21: 113.
-
(1983)
Urology
, vol.21
, pp. 113
-
-
Lange, P.H.1
Narayan, P.2
-
3
-
-
0025679195
-
Role of nerve sparing radical prostatectomy for clinical stage B2 prostate cancer
-
Bigg SW, Kavoussi LR, Catalona WJ. Role of nerve sparing radical prostatectomy for clinical stage B2 prostate cancer. J Urol 1990; 144: 1420.
-
(1990)
J Urol
, vol.144
, pp. 1420
-
-
Bigg, S.W.1
Kavoussi, L.R.2
Catalona, W.J.3
-
4
-
-
0023493310
-
Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule
-
Anscher MS, Prosnitz LR. Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 1987; 138: 1407.
-
(1987)
J Urol
, vol.138
, pp. 1407
-
-
Anscher, M.S.1
Prosnitz, L.R.2
-
5
-
-
0025301752
-
Resection margin status in radical retropubic prostatectomy specimens: Relationship to type of operation, tumor size, tumor grade and local tumor extension
-
Jones EC. Resection margin status in radical retropubic prostatectomy specimens: Relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol 1990; 144: 89.
-
(1990)
J Urol
, vol.144
, pp. 89
-
-
Jones, E.C.1
-
6
-
-
0027845218
-
Down staging of localized prostate cancer by neoadjuvant therapy with flutamide and lupon: The first controlled and randomized trial
-
Labrie F, Dupon A, Cusan L et al. Down staging of localized prostate cancer by neoadjuvant therapy with flutamide and lupon: The first controlled and randomized trial. Clin Invest Med 1993; 16: 499-509.
-
(1993)
Clin Invest Med
, vol.16
, pp. 499-509
-
-
Labrie, F.1
Dupon, A.2
Cusan, L.3
-
7
-
-
0029059020
-
Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2(T2bNXMO) prostate cancer
-
The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
-
Soloway MS, Sharifi R, Wajsman Z et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2(T2bNXMO) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995; 154: 424-8.
-
(1995)
J Urol
, vol.154
, pp. 424-428
-
-
Soloway, M.S.1
Sharifi, R.2
Wajsman, Z.3
-
8
-
-
0029656221
-
Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer
-
Gleave ME, Goldenberg SL, Jones EC et al. Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996; 155: 213-9.
-
(1996)
J Urol
, vol.155
, pp. 213-219
-
-
Gleave, M.E.1
Goldenberg, S.L.2
Jones, E.C.3
-
9
-
-
0029016831
-
2 prostate cancer: Interim results of a prospective randomize trial
-
2 prostate cancer: Interim results of a prospective randomize trial. J Urol 1995; 154: 429.
-
(1995)
J Urol
, vol.154
, pp. 429
-
-
Van Poppel, H.1
De Ridder, D.2
Elgamal, A.3
-
11
-
-
1542714492
-
Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study
-
Vailancourt L, Ttu B, Fradet Y et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol 1996; 20: 86-91.
-
(1996)
Am J Surg Pathol
, vol.20
, pp. 86-91
-
-
Vailancourt, L.1
Ttu, B.2
Fradet, Y.3
-
12
-
-
0032412924
-
Hormonal treatment before radical prostatectomy: A three-year follow-up
-
Aus G, Abrahamsson PA et al. Hormonal treatment before radical prostatectomy: A three-year follow-up. J Urol 1998; 159 (6): 2013-6.
-
(1998)
J Urol
, vol.159
, Issue.6
, pp. 2013-2016
-
-
Aus, G.1
Abrahamsson, P.A.2
-
13
-
-
0023680206
-
Adjuvant estrogen following radiation therapy for stage C carcinoma of the prostate: Long-term results of a prospective randomized trial
-
Zagars GK et al. Adjuvant estrogen following radiation therapy for stage C carcinoma of the prostate: Long-term results of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1988; 14: 1085-91.
-
(1988)
Int J Radiat Oncol Biol Phys
, vol.14
, pp. 1085-1091
-
-
Zagars, G.K.1
-
14
-
-
0015749215
-
The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate
-
Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126-30.
-
(1973)
Cancer
, vol.32
, pp. 1126-1130
-
-
Byar, D.P.1
-
15
-
-
0030856678
-
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
-
Bolla M et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
-
(1997)
N Engl J Med
, vol.337
, pp. 295-300
-
-
Bolla, M.1
-
16
-
-
0028880521
-
Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group
-
Pilepich MV et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45 (4): 616-23.
-
(1995)
Urology
, vol.45
, Issue.4
, pp. 616-623
-
-
Pilepich, M.V.1
-
17
-
-
0031051097
-
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31
-
Pilepich MV et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997; 15: 1013-21.
-
(1997)
J Clin Oncol
, vol.15
, pp. 1013-1021
-
-
Pilepich, M.V.1
-
18
-
-
0028173105
-
The biologic basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate
-
Leibel SA, Zelefsky MJ, G. Kutcher. The biologic basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 1994; 21: 580-92.
-
(1994)
Semin Oncol
, vol.21
, pp. 580-592
-
-
Leibel, S.A.1
Zelefsky, M.J.2
Kutcher, G.3
-
19
-
-
0030657664
-
Cost benefit of emerging technology in localized carcinoma of the prostate
-
Perez CA et al. Cost benefit of emerging technology in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997; 39: 875-87.
-
(1997)
Int J Radiat Oncol Biol Phys
, vol.39
, pp. 875-887
-
-
Perez, C.A.1
-
20
-
-
0026778629
-
Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: A reduction in acute morbidity
-
Soffen EM et al. Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: A reduction in acute morbidity. Int J Radiat Oncol Biol Phys 1992; 24: 485-91.
-
(1992)
Int J Radiat Oncol Biol Phys
, vol.24
, pp. 485-491
-
-
Soffen, E.M.1
-
21
-
-
0029941575
-
Lateral rectal shielding reduces late rectal morbidity following high-dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a signficant dose effect
-
Lee WR et al. Lateral rectal shielding reduces late rectal morbidity following high-dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a signficant dose effect. Int J Radiat Oncol Biol Phys 1996; 35: 251-7.
-
(1996)
Int J Radiat Oncol Biol Phys
, vol.35
, pp. 251-257
-
-
Lee, W.R.1
-
22
-
-
0000624946
-
Three-dimensional conformal radiotherapy and dose escalation: Where do we stand?
-
Zelefsky MJ et al. Three-dimensional conformal radiotherapy and dose escalation: Where do we stand? Semin Radiat Oncol 1998; 8: 107-14.
-
(1998)
Semin Radiat Oncol
, vol.8
, pp. 107-114
-
-
Zelefsky, M.J.1
-
23
-
-
0029013018
-
Clinical and biochemical evidence of control of prostate cancer at five years after external beam radiation
-
Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at five years after external beam radiation. J Urol 1995; 154: 456-9.
-
(1995)
J Urol
, vol.154
, pp. 456-459
-
-
Hanks, G.E.1
Lee, W.R.2
Schultheiss, T.E.3
-
24
-
-
0030586031
-
Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > 10 ng/ml
-
Hanks GE et al. Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > 10 ng/ml. Int J Radiat Oncol Biol Phys 1996; 35: 861-8.
-
(1996)
Int J Radiat Oncol Biol Phys
, vol.35
, pp. 861-868
-
-
Hanks, G.E.1
-
25
-
-
0028910506
-
Advanced prostate cancer: The results of a randomized comparative trial of high-dose irradiation boosting with conformal protons compared with conventional-dose irradiation using photons alone
-
Shipley WU et al. Advanced prostate cancer: The results of a randomized comparative trial of high-dose irradiation boosting with conformal protons compared with conventional-dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995; 32: 3-12.
-
(1995)
Int J Radiat Oncol Biol Phys
, vol.32
, pp. 3-12
-
-
Shipley, W.U.1
-
26
-
-
0030456068
-
Should brachytherapy be considered a therapeutic option in localized prostate cancer?
-
Blasko JC et al. Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin N Am 1996; 23: 633-50.
-
(1996)
Urol Clin N Am
, vol.23
, pp. 633-650
-
-
Blasko, J.C.1
-
27
-
-
0030778649
-
Brachytherapy for clinically localized prostate cancer. Results at seven- and eight-year follow-up
-
Ragde H, Blasko JC, Grimm PD. Brachytherapy for clinically localized prostate cancer. Results at seven- and eight-year follow-up. Semin Surg Oncol 1997; 13: 438-46.
-
(1997)
Semin Surg Oncol
, vol.13
, pp. 438-446
-
-
Ragde, H.1
Blasko, J.C.2
Grimm, P.D.3
-
28
-
-
0030947222
-
Long-term results of retropubic permanent I-125 implant of the prostate for clinically localized prostate cancer
-
Zelefsky MJ et al. Long-term results of retropubic permanent I-125 implant of the prostate for clinically localized prostate cancer. J Urol 1998; 158: 23-9.
-
(1998)
J Urol
, vol.158
, pp. 23-29
-
-
Zelefsky, M.J.1
-
29
-
-
0030887902
-
The PSA nadir that indicates potential cure after radiotherapy for prostate cancer
-
Critz FA et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 1997; 49: 322-31.
-
(1997)
Urology
, vol.49
, pp. 322-331
-
-
Critz, F.A.1
-
30
-
-
0031051524
-
Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer
-
Prestidge BR et al. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 31-8.
-
(1997)
Int J Radiat Oncol Biol Phys
, vol.37
, pp. 31-38
-
-
Prestidge, B.R.1
-
31
-
-
0032538069
-
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
-
D'Amico AV et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74.
-
(1998)
JAMA
, vol.280
, pp. 969-974
-
-
D'Amico, A.V.1
-
32
-
-
0031403675
-
Immediate versus deferred treatment for advanced prostate cancer: Initial results of the Medical Research Council trial
-
The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostate cancer: Initial results of the Medical Research Council trial. Br J Urol 1997; 79; 235-46.
-
(1997)
Br J Urol
, vol.79
, pp. 235-246
-
-
-
33
-
-
0030816124
-
Combined androgen blockade: The gold standard for metastatic prostate cancer
-
McLead DG et al. Combined androgen blockade: The gold standard for metastatic prostate cancer. Eur Urol 1997; 32 (Suppl 3): 70-7.
-
(1997)
Eur Urol
, vol.32
, Issue.3 SUPPL.
, pp. 70-77
-
-
McLead, D.G.1
-
34
-
-
0024324367
-
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
-
Crawford ED et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-29.
-
(1989)
N Engl J Med
, vol.321
, pp. 419-429
-
-
Crawford, E.D.1
-
35
-
-
0032497522
-
A comparison of bilateral orchiectomy with or without flutamide in stage D2 prostate cancer
-
Eisenberger MA. A comparison of bilateral orchiectomy with or without flutamide in stage D2 prostate cancer. N Engl J Med 1998; 339: 1036-42.
-
(1998)
N Engl J Med
, vol.339
, pp. 1036-1042
-
-
Eisenberger, M.A.1
-
36
-
-
0032556218
-
Quality of life in advanced prostate cancer: Results of a randomized therapeutic trial
-
Moinpour CM et al. Quality of life in advanced prostate cancer: Results of a randomized therapeutic trial. J Natl Cancer Inst 1998; 90: 1537-44.
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 1537-1544
-
-
Moinpour, C.M.1
-
37
-
-
0029103141
-
Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients
-
Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-9.
-
(1995)
Lancet
, vol.346
, pp. 265-269
-
-
-
38
-
-
0031038373
-
Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens
-
Caubet JF et al. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997; 49: 71-8.
-
(1997)
Urology
, vol.49
, pp. 71-78
-
-
Caubet, J.F.1
-
39
-
-
0031869236
-
A pilot study of intermittent androgen deprivation in advanced prostate cancer
-
Horwich A et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 1998; 81: 96-9.
-
(1998)
Br J Urol
, vol.81
, pp. 96-99
-
-
Horwich, A.1
-
40
-
-
0345060642
-
Intermittent hormone blockade: Optimal induction duration and predictive factors for prolonged time off hormone blockade
-
Strum SB et al. Intermittent hormone blockade: Optimal induction duration and predictive factors for prolonged time off hormone blockade. Proc ASCO 1998; 17.
-
(1998)
Proc ASCO
, pp. 17
-
-
Strum, S.B.1
-
41
-
-
0030297953
-
Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study
-
Higano CS et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study. Urology 1996; 48: 800-4.
-
(1996)
Urology
, vol.48
, pp. 800-804
-
-
Higano, C.S.1
-
42
-
-
0028892410
-
Intermittent androgen suppresion in the treatment of prostate cancer: A preliminary report
-
Goldenburg SL et al. Intermittent androgen suppresion in the treatment of prostate cancer: A preliminary report. Urology 1995; 45: 839-45.
-
(1995)
Urology
, vol.45
, pp. 839-845
-
-
Goldenburg, S.L.1
-
43
-
-
0022997273
-
Intermittent endocrine therapy for advanced prostate cancer
-
Klotz LH et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 2546-50.
-
(1986)
Cancer
, vol.58
, pp. 2546-2550
-
-
Klotz, L.H.1
-
44
-
-
0031010962
-
Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate
-
Brufsky A et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997; 49: 913-20.
-
(1997)
Urology
, vol.49
, pp. 913-920
-
-
Brufsky, A.1
-
45
-
-
0344630038
-
Secondary hormonal responses after initial peripheral androgen ablation therapy with finasteride and flutamide in advanced prostate cancer
-
Oh W et al. Secondary hormonal responses after initial peripheral androgen ablation therapy with finasteride and flutamide in advanced prostate cancer. Proc ASCO 1998; 17.
-
(1998)
Proc ASCO
, pp. 17
-
-
Oh, W.1
-
46
-
-
4243465490
-
Bicalutamide monotherapy versus flutamide plus gosrelin in prostate cancer patients. Preliminary results of an Italian Prostate Cancer Group Study
-
Boccardo F et al. Bicalutamide monotherapy versus flutamide plus gosrelin in prostate cancer patients. Preliminary results of an Italian Prostate Cancer Group Study. Proc ASCO 1997; 16.
-
(1997)
Proc ASCO
, pp. 16
-
-
Boccardo, F.1
-
47
-
-
85037933923
-
Improvements in subjective response in patients with advanced prostate cancer treated with 'casodex' (bicalutamide) 150 mg mono-therapy compared with castration
-
Tyrell CJ et al. Improvements in subjective response in patients with advanced prostate cancer treated with 'casodex' (bicalutamide) 150 mg mono-therapy compared with castration. Proc ASCO 1998; 17.
-
(1998)
Proc ASCO
, pp. 17
-
-
Tyrell, C.J.1
-
48
-
-
0030861185
-
Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer
-
Pummer K et al. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997; 32 (Suppl 3): 81-5.
-
(1997)
Eur Urol
, vol.32
, Issue.3 SUPPL.
, pp. 81-85
-
-
Pummer, K.1
-
49
-
-
0030933345
-
Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multi-center study of ochiectomy alone versus orchiectomy plus estramustine phosphate
-
Janknegt RA et al. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multi-center study of ochiectomy alone versus orchiectomy plus estramustine phosphate. Urology 1997; 49: 411-20.
-
(1997)
Urology
, vol.49
, pp. 411-420
-
-
Janknegt, R.A.1
-
50
-
-
0345060640
-
Androgen deprivation + four courses of fixed-schedule suramin in D2 prostate cancer patients: A Southwest Oncology Group phase II study
-
Hussain M et al. Androgen deprivation + four courses of fixed-schedule suramin in D2 prostate cancer patients: A Southwest Oncology Group phase II study. Proc ASCO 1998; 17.
-
(1998)
Proc ASCO
, pp. 17
-
-
Hussain, M.1
-
51
-
-
17144469967
-
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer
-
Dawson NA et al. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997; 15: 1470-7.
-
(1997)
J Clin Oncol
, vol.15
, pp. 1470-1477
-
-
Dawson, N.A.1
-
52
-
-
0031017228
-
Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
-
Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm. J Clin Oncol 1997; 15: 382-8.
-
(1997)
J Clin Oncol
, vol.15
, pp. 382-388
-
-
Small, E.J.1
Vogelzang, N.J.2
-
53
-
-
0030971169
-
Antiandrogen withdrawal syndrome with nilutamide
-
Huan SD, Gerridzen RG et al. Antiandrogen withdrawal syndrome with nilutamide. Urology 1997; 49: 632-4.
-
(1997)
Urology
, vol.49
, pp. 632-634
-
-
Huan, S.D.1
Gerridzen, R.G.2
-
54
-
-
0030999075
-
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal
-
Small EJ et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 157: 1204-7.
-
(1997)
J Urol
, vol.157
, pp. 1204-1207
-
-
Small, E.J.1
-
55
-
-
0030695382
-
Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortizone in patients with advanced prostate carcinoma
-
Small EJ et al. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortizone in patients with advanced prostate carcinoma. Cancer 1997; 80: 1755-9.
-
(1997)
Cancer
, vol.80
, pp. 1755-1759
-
-
Small, E.J.1
-
56
-
-
18244419285
-
Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPRCA study 9002
-
Iverson P et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPRCA study 9002. J Urol 1997; 157: 929-34.
-
(1997)
J Urol
, vol.157
, pp. 929-934
-
-
Iverson, P.1
-
57
-
-
0030747033
-
Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
-
Hudes GR et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15: 3156-63.
-
(1997)
J Clin Oncol
, vol.15
, pp. 3156-3163
-
-
Hudes, G.R.1
-
58
-
-
0030965020
-
A phase II study of oral idarubicin as treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time
-
Schhmid HP et al. A phase II study of oral idarubicin as treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Cancer 1997; 79: 1703-9.
-
(1997)
Cancer
, vol.79
, pp. 1703-1709
-
-
Schhmid, H.P.1
-
59
-
-
0030711034
-
Oral estramustine and oral etoposide for hormone-refractory prostate cancer
-
Dimopoulos MA et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 1997; 50: 754-8.
-
(1997)
Urology
, vol.50
, pp. 754-758
-
-
Dimopoulos, M.A.1
-
60
-
-
0030782928
-
A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer
-
Pienta KJ et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 1997; 50: 401-7.
-
(1997)
Urology
, vol.50
, pp. 401-407
-
-
Pienta, K.J.1
-
61
-
-
0030835839
-
Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer
-
Colleoni M et al. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer Am J Clin Oncol 1997; 20; 383-6.
-
(1997)
Am J Clin Oncol
, vol.20
, pp. 383-386
-
-
Colleoni, M.1
-
62
-
-
0030927778
-
Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: A phase II study
-
Hernes EH et al. Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: A phase II study. Br J Cancer 1997; 76: 93-9.
-
(1997)
Br J Cancer
, vol.76
, pp. 93-99
-
-
Hernes, E.H.1
-
63
-
-
0030763677
-
Suramin/epidoxorubicin association in hormone-refractory prostate cancer: Preliminary results of a pilot phase II study
-
Miglietta L et al. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: Preliminary results of a pilot phase II study. J Cancer Res Clin Oncol 1997; 123: 407-10.
-
(1997)
J Cancer Res Clin Oncol
, vol.123
, pp. 407-410
-
-
Miglietta, L.1
-
64
-
-
0030997896
-
Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer
-
Raghavan D et al. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 1997; 33: 566-74.
-
(1997)
Eur J Cancer
, vol.33
, pp. 566-574
-
-
Raghavan, D.1
-
65
-
-
17444436904
-
Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer
-
Pienta KJ, Smith DC. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Semin Oncol 1997; 24 (Suppl 15): 72-7.
-
(1997)
Semin Oncol
, vol.24
, Issue.15 SUPPL.
, pp. 72-77
-
-
Pienta, K.J.1
Smith, D.C.2
-
66
-
-
0031431760
-
Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer
-
Ellerhorst JA et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 1997; 3: 2371-6.
-
(1997)
Clin Cancer Res
, vol.3
, pp. 2371-2376
-
-
Ellerhorst, J.A.1
-
67
-
-
0001022989
-
Superiority of suramin + hydrocortisone over placebo + hydrocortisone: Results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer
-
Small EJ et al. Superiority of suramin + hydrocortisone over placebo + hydrocortisone: Results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer. Proc ASCO 1998; 17.
-
(1998)
Proc ASCO
, pp. 17
-
-
Small, E.J.1
|